Gilead Sciences, Inc. with price, financials, news flow, and insider context in one page.
Gilead Sciences, Inc. is being tracked here through price action, operating context, and headline flow. This public page covers the latest market move, where GILD sits inside Healthcare and Drug Manufacturers - General, and the key financial markers that matter before moving into a fuller research workflow.
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. Additionally, the company engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.
This page is structured for research context, not a trade call. It gives you a clean read on where GILD sits in its range, what the last few quarters look like, and which headlines are shaping attention.
For position sizing, alerts, saved watchlists, and deeper analysis workflows, the next step is the logged-in Meridian workspace.
| Quarter | Revenue | Net income | Free cash flow |
|---|---|---|---|
| Q1 2026 | 6.96B | 2.02B | 2.43B |
| Q4 2025 | 7.92B | 2.18B | 3.12B |
| Q3 2025 | 7.77B | 3.05B | 3.96B |
| Q2 2025 | 7.08B | 1.96B | 720M |
The attacks come as the United States and Iran are supposed to be engaging in a 60-day ceasefire as they attempt to work toward a resolution.
See the next report date, earnings cadence, and reporting context.
Open a side-by-side comparison page to frame valuation and growth.
Read open desk notes tied to sectors, macro themes, and active names.
Learn the framework behind valuation, momentum, and risk before you act.
Gilead Sciences, Inc. (GILD) — questions investors ask
What is the current stock price of Gilead Sciences, Inc. (GILD)?
Gilead Sciences, Inc. (GILD) is trading at $127.88, up 3.26% in the latest session. The live price and one-year chart on this page update through the trading day.
What is Gilead Sciences, Inc.'s market capitalization?
Gilead Sciences, Inc. has a market capitalization of about 158.77B, derived from the latest share price and shares outstanding.
When is Gilead Sciences, Inc.'s next earnings date?
Gilead Sciences, Inc. is next expected to report earnings on Aug 6, 2026. The GILD earnings page tracks the estimate and reporting history.
What is Gilead Sciences, Inc.'s P/E ratio?
Gilead Sciences, Inc. trades at a forward price-to-earnings ratio of 13.22 — one measure of how the market is pricing its future earnings.
What is GILD's 52-week trading range?
Over the past 52 weeks, GILD has traded between $107.75 and $157.29.
What sector is Gilead Sciences, Inc. in?
Gilead Sciences, Inc. operates in the Healthcare sector, within the Drug Manufacturers - General industry.
Does Gilead Sciences, Inc. pay a dividend?
Gilead Sciences, Inc. currently carries a dividend yield of about 100.0%.
What is the analyst price target for GILD?
The mean analyst price target for GILD is $157.57, with an overall analyst view of Buy.
A public stock page should answer the first research questions before asking for a signup.
This GILD page is designed for public research utility. You can read the latest session move, check the one-year chart, review a compact financial table, scan recent headlines, and compare adjacent names without immediately moving into a gated dashboard.
The logged-in Meridian workflow goes further with saved watchlists, deeper analysis, alert routing, and recurring review systems. The public layer is meant to be credible and indexable on its own, not a hollow teaser page.